Identification of metabotropic glutamate receptor subtype 5 potentiators using virtual high-throughput screening

ACS Chemical Neuroscience

Volumn 1, Issue 4, 2010, Pages 288-305

  Mueller, Ralf ^a   Rodriguez, Alice L ^a   Dawson, Eric S ^b   Butkiewicz, Mariusz ^a   Nguyen, Thuy T ^a   Oleszkiewicz, Stephen ^a   Bleckmann, Annalen ^a   Weaver, C David ^a,b   Lindsley, Craig W ^a,b   Conn, P Jeffrey ^a,b   Meiler, Jens ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BENZENE DERIVATIVE; BENZOXAZEPINE DERIVATIVE; METABOTROPIC RECEPTOR 5; PHENYL GROUP; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL NEURAL NETWORK; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; MOLECULAR MODEL; PREDICTION; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

EID: 77951688576     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn9000389     Document Type: Article

References (77)

1. Conn, P. J. and Pin, J. P. (1997) Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37, 205-237
2. Pin, J. P. and Duvoisin, R. (1995) The metabotropic glutamate receptors: structure and functions Neuropharmacology 34 (1) 1-26
3. Palucha, A. and Pilc, A. (2002) On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants Pol. J. Pharmacol. 54 (6) 581-586
4. Chojnacka-Wojcik, E., Klodzinska, A., and Pilc, A. (2001) Glutamate receptor ligands as anxiolytics Curr. Opin. Invest. Drugs 2 (8) 1112-1119
5. Pilc, A. (2003) LY-354740 (Eli Lilly) IDrugs 6 (1) 66-71
6. Marino, M. J. and Conn, P. J. (2002) Direct and indirect modulation of the N-methyl D-aspartate receptor Curr. Drug Targets CNS Neurol. Disord. 1 (1) 1-16
7. Chavez-Noriega, L. E., Schaffhauser, H., and Campbell, U. C. (2002) Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia Curr. Drug Targets CNS Neurol. Disord. 1 (3) 261-281
8. Conn, P. J., Lindsley, C. W., and Jones, C. K. (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia Trends Pharmacol. Sci. 30 (1) 25-31
9. Ayala, J. E.; Chen, Y.; Banko, J. L.; Sheffler, D. J.; Williams, R.; Telk, A. N.; Watson, N. L.; Xiang, Z.; Zhang, Y.; Jones, P. J.; Lindsley, C. W.; Olive, M. F.; Conn, P. J. mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning Neuropsychopharmacology 2009, 34 (9) 2057-2071
10. Varney, M. A. and Gereau, R. W. t. (2002) Metabotropic glutamate receptor involvement in models of acute and persistent pain: prospects for the development of novel analgesics Curr. Drug Targets CNS Neurol. Disord. 1 (3) 283-296
11. Doherty, J. and Dingledine, R. (2002) The roles of metabotropic glutamate receptors in seizures and epilepsy Curr. Drug Targets CNS Neurol. Disord. 1 (3) 251-260
12. Wisniewski, K. and Car, H. (2002) (S)-3,5-DHPG: a review CNS Drug Rev. 8 (1) 101-116
13. Marino, M. J. and Conn, J. P. (2002) Modulation of the basal ganglia by metabotropic glutamate receptors: potential for novel therapeutics Curr. Drug Targets CNS Neurol. Disord. 1 (3) 239-250
14. Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J., and Conn, P. J. (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J. Pharmacol. Exp. Ther. 306 (1) 116-123
15. Henry, S. A., Lehmann-Masten, V., Gasparini, F., Geyer, M. A., and Markou, A. (2002) The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity Neuropharmacology 43 (8) 1199-1209
16. Campbell, U. C., Lalwani, K., Hernandez, L., Kinney, G. G., Conn, P. J., and Bristow, L. J. (2004) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)- pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats Psychopharmacology (Berlin) 175 (3) 310-318
17. Brody, S. A., Dulawa, S. C., Conquet, F., and Geyer, M. A. (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors Mol. Psychiatry 9 (1) 35-41
18. O'Brien, J. A., Lemaire, W., Chen, T. B., Chang, R. S., Jacobson, M. A., Ha, S. N., Lindsley, C. W., Schaffhauser, H. J., Sur, C., Pettibone, D. J., Conn, P. J., and Williams, D. L., Jr. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 Mol. Pharmacol. 64 (3) 731-740
19. O'Brien, J. A., Lemaire, W., Wittmann, M., Jacobson, M. A., Ha, S. N., Wisnoski, D. D., Lindsley, C. W., Schaffhauser, H. J., Rowe, B., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, P. J., and Williams, D. L., Jr. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain J. Pharmacol. Exp. Ther. 309 (2) 568-577
20. Lindsley, C. W., Wisnoski, D. D., Leister, W. H., O'Brien, J, A., Lemaire, W., Williams, D. L., Jr., Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., Tiller, P. R., Smith, S., Duggan, M. E., Hartman, G. D., Conn, P. J., and Huff, J. R. (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo J. Med. Chem. 47 (24) 5825-5828
21. Kinney, G. G., O'Brien, J. A., Lemaire, W., Burno, M., Bickel, D. J., Clements, M. K., Chen, T. B., Wisnoski, D. D., Lindsley, C. W., Tiller, P. R., Smith, S., Jacobson, M. A., Sur, C., Duggan, M. E., Pettibone, D. J., Conn, P. J., and Williams, D. L., Jr. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models J. Pharmacol. Exp. Ther. 313 (1) 199-206
22. de Paulis, T., Hemstapat, K., Chen, Y., Zhang, Y., Saleh, S., Alagille, D., Baldwin, R. M., Tamagnan, G. D., and Conn, P. J. (2006) Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes J. Med. Chem. 49 (11) 3332-3344
23. Engers, D. W., Rodriguez, A. L., Williams, R., Hammond, A. S., Venable, D., Oluwatola, O., Sulikowski, G. A., Conn, P. J., and Lindsley, C. W. (2009) Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 Ago-potentiator ADX-47273 ChemMedChem 4 (4) 505-511
24. Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X., Smith, D., Olsen, M., Kouranova, E., Lai, M., Pruthi, F., Pulicicchio, C., Day, M., Gilbert, A., Pausch, M. H., Brandon, N. J., Beyer, C. E., Comery, T. A., Logue, S., Rosenzweig-Lipson, S., and Marquis, K. L. (2008) ADX47273 [S-(4-fluoro-phenyl)- {3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities J. Pharmacol. Exp. Ther. 327 (3) 827-839
25. Bessis, A.-S. B. B., Le Poul, E., Rocher, J.-P., and Epping-Jordan, M. (2005) Preparation of piperidine derivatives as modulators of metabotropic glutamate receptors (mGluR5), WO 044797.
26. Bugada, P. G. S., Le Poul, E., Mutel, V., Palombi, G., and Rocher, J.-P. (2006) Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors and their preparation, pharmaceutical compositions and use in the treatment of central and peripheral nervous system disorders, WO 6123249.
27. Chen, Y., Goudet, C., Pin, J. P., and Conn, P. J. (2008) N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors Mol. Pharmacol. 73 (3) 909-918
28. Sharma, S., Rodriguez, A. L., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg. Med. Chem. Lett. 18 (14) 4098-4101
29. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analog of 2-methyl-6- (phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators Mol. Pharmacol. 68 (6) 1793-1802
30. Liu, B., Li, S., and Hu, J. (2004) Technological advances in high-throughput screening Am. J. Pharmacogenomics 4 (4) 263-276
31. Carnero, A. (2006) High throughput screening in drug discovery Clin. Trans. Oncol. 8 (7) 482-490
32. Hodder, P., Mull, R., Cassaday, J., Berry, K., and Strulovici, B. (2004) Miniaturization of intracellular calcium functional assays to 1536-well plate format using a fluorometric imaging plate reader J. Biomol. Screening 9 (5) 417-426
33. Gilchrist, M. A., II, Cacace, A., and Harden, D. G. (2008) Characterization of the 5-HT2b receptor in evaluation of aequorin detection of calcium mobilization for miniaturized GPCR high-throughput screening J. Biomol Screening 13 (6) 486-493
34. Posner, B. A. (2005) High-throughput screening-driven lead discovery: meeting the challenges of finding new therapeutics Curr. Opin. Drug Discovery Dev. 8 (4) 487-494
35. Todeschini, R. and Consonni, V. (2000) Handbook of Molecular Descriptors, Vol. 11, Wiley-VCH, Weinheim, Germany.
36. Hansch, C., Hoekman, D., Leo, A., Weininger, D., and Selassie, C. D. (2002) Chem-bioinformatics: comparative QSAR at the interface between chemistry and biology Chem. Rev. 102 (3) 783-812
37. Hansch, C. M., Peyton, P., Fujita, Toshio, and Muir, Robert M. (1962) Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients Nature 194, 178-180
38. Bleckmann, A. and Meiler, J. (2003) Epothilones: quantitative structure activity relations studied by support vector machines and artificial neural networks QSAR Comb. Sci. 22 (7) 719-721
39. Tetko, I. V., Sushko, I., Pandey, A. K., Zhu, H., Tropsha, A., Papa, E., Oberg, T., Todeschini, R., Fourches, D., and Varnek, A. (2008) Critical assessment of QSAR models of environmental toxicity against Tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection J. Chem. Inf. Model. 48 (9) 1733-1746
40. Winkler, D. (2004) Neural networks as robust tools in drug lead discovery and development Mol. Biotechnol. 27 (2) 139-167
41. Cramer, R. D., III, Patterson, D. E., and Bunce, J. D. (1989) Recent advances in comparative molecular field analysis (CoMFA) Prog. Clin. Biol. Res. 291, 161-165
42. Cramer, R. D., Patterson, D. E., and Bunce, J. D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 110 (18) 5959-5967
43. Klebe, G., Abraham, U., and Mietzner, T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity J. Med. Chem. 37 (24) 4130-4146
44. Wild, D. J. and Blankley, C. J. (2000) Comparison of 2D fingerprint types and hierarchy level selection methods for structural grouping using Ward's clustering J. Chem. Inf. Comput. Sci. 40 (1) 155-162
45. Krasowski, M. D., Siam, M. G., Iyer, M., and Ekins, S. (2009) Molecular Similarity Methods for Predicting Cross-Reactivity With Therapeutic Drug Monitoring Immunoassays Ther. Drug Monit. 31 (3) 337-344
46. Moda, T. L., Montanari, C. A., and Andricopulo, A. D. (2007) Hologram QSAR model for the prediction of human oral bioavailability Bioorg. Med. Chem. 15 (24) 7738-7745
47. Salum, L. B. and Andricopulo, A. D. (2009) Fragment-based QSAR: perspectives in drug design Mol. Divers. 13, 277-285
48. Heritage, T. W. and Hurst, T. (1997) HQSAR: a highly predictive QSAR technique based on molecular holograms, Book of Abstracts, 214th ACS National Meeting, Las Vegas, NV, Sep 7-11, COMP-080.
49. Waller, C. L. (2004) A comparative QSAR study using CoMFA, HQSAR, and FRED/SKEYS paradigms for estrogen receptor binding affinities of structurally diverse compounds J. Chem. Inf. Comput. Sci. 44 (2) 758-765
50. Vogt, I., Ahmed, H. E., Auer, J., and Bajorath, J. (2008) Exploring structure-selectivity relationships of biogenic amine GPCR antagonists using similarity searching and dynamic compound mapping Mol. Divers. 12 (1) 25-40
51. Brown, R. D. and Martin, Y. C. (1996) Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection J. Chem. Inf. Comput. Sci. 36 (3) 572-584
52. Jenkins, J. L., Glick, M., and Davies, J. W. (2004) A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes J. Med. Chem. 47 (25) 6144-6159
53. Nettles, J. H., Jenkins, J. L., Williams, C., Clark, A. M., Bender, A., Deng, Z., Davies, J. W., and Glick, M. (2007) Flexible 3D pharmacophores as descriptors of dynamic biological space J. Mol. Graphics Modell. 26 (3) 622-633
54. Marrero-Ponce, Y. (2004) Linear indices of the molecular pseudographs atom adjacency matrix: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors J. Chem. Inf. Comput. Sci. 44 (6) 2010-2026
55. Gonzalez, M. P., Puente, M., Fall, Y., and Gomez, G. (2006) In silico studies using Radial Distribution Function approach for predicting affinity of 1 alpha,25-dihydroxyvitamin D(3) analogues for Vitamin D receptor Steroids 71 (6) 510-527
56. Morales, A. H., Cabrera Perez, M. A., and Gonzalez, M. P. (2006) A radial-distribution-function approach for predicting rodent carcinogenicity J. Mol. Model. 12 (6) 769-780
57. Computerchemie, M. N. G., Schwab, C. H., and Gasteiger, J. (2006) ADRIANA.Code; Algorithms for the Encoding of Molecular Structures, version 2.0, program description, Molecular Networks GmbH, Erlangen, Germany.
58. Bauknecht, H., Zell, A., Bayer, H., Levi, P., Wagener, M., Sadowski, J., and Gasteiger, J. (1996) Locating biologically active compounds in medium-sized heterogeneous datasets by topological autocorrelation vectors: dopamine and benzodiazepine agonists J. Chem. Inf. Comput. Sci. 36 (6) 1205-1213
59. Hristozov, D. P., Oprea, T. I., and Gasteiger, J. (2007) Virtual screening applications: a study of ligand-based methods and different structure representations in four different scenarios J. Comput.-Aided Mol. Des. 21 (10-11) 617-640
60. Hristozov, D., Oprea, T. I., and Gasteiger, J. (2007) Ligand-based virtual screening by novelty detection with self-organizing maps J. Chem. Inf. Model. 47 (6) 2044-2062
61. Anzali, S., Barnickel, G., Krug, M., Sadowski, J., Wagener, M., Gasteiger, J., and Polanski, J. (1996) The comparison of geometric and electronic properties of molecular surfaces by neural networks: application to the analysis of corticosteroid-binding globulin activity of steroids J. Comput.-Aided Mol. Des. 10 (6) 521-534
62. Holzgrabe, U., Wagener, M., and Gasteiger, J. (1996) Comparison of structurally different allosteric modulators of muscarinic receptors by self-organizing neural networks J. Mol. Graphics 14 (4) 185-193
63. Teckentrup, A., Briem, H., and Gasteiger, J. (2004) Mining high-throughput screening data of combinatorial libraries: development of a filter to distinguish hits from nonhits J. Chem. Inf. Comput. Sci. 44 (2) 626-634
64. Zupan, J. and Gasteiger, J. (1993) Neural Networks for Chemists, VCH Verlagsgesellschaft mbH, Weinheim, Germany.
65. Burton, J., Ijjaali, I., Barberan, O., Petitet, F., Vercauteren, D. P., and Michel, A. (2006) Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset J. Med. Chem. 49 (21) 6231-6240
66. Hecht, D., Cheung, M., and Fogel, G. B. (2008) QSAR using evolved neural networks for the inhibition of mutant PfDHFR by pyrimethamine derivatives Biosystems 92 (1) 10-15
67. Hecht, D. and Fogel, G. (2007) High-throughput ligand screening via preclustering and evolved neural networks IEEE/ACM Trans. Comput. Biol. Bioinformatics 4 (3) 476-484
68. Butkiewicz, M., Mueller, R., Selic, D., Dawson, E., and Meiler, J. (2009) Application of Machine Learning Approaches on Quantitative Structure Activity Relationships, in IEEE CIBCB 2009: 2009 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology, pp 255 - 262, IEEE Computational Intelligence Society, Nashville, TN.
69. Lipinski, C. A. (2004) Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technologies 1 (4) 337-341
70. Gedeck, P., Rohde, B., and Bartels, C. (2006) QSAR - how good is it in practice? Comparison of descriptor sets on an unbiased cross section of corporate data sets J. Chem. Inf. Model. 46 (5) 1924-1936
71. Willett, P. (2006) Similarity-based virtual screening using 2D fingerprints Drug Discovery Today 11 (23-24) 1046-1053
72. Wolfram Research, I. (2008) Mathematica, version 7, Wolfram Research, Inc., Champaigne, IL.
73. Gasteiger, J., Rudolph, C., and Sadowski, J. (1990) Automatic generation of 3D atomic coordinates for organic molecules Tetrahedron Comput. Methodol. 3 (6c) 537-457
74. Schwab, C. H. (2007) ADRIANA.Code, 2.0, Molecular Networks GmbH, Erlangen, Germany.
75. Schoelkopf, B. and Smola, A. J. (2002) Learning with Kernels, The MIT Press, Cambridge, MA.
76. Riedmiller, M. and Braun, H. (1992) Rprop-A Fast Adaptive Learning Algorithm, Proceedings of the International Symposium on Computer and Information Science VII, pp. 279 - 286, IEEE, Antalya, Turkey.
77. Meiler, J., Muller, M., Zeidler, A., and Schmaschke, F. (2001) Generation and evaluation of dimension-reduced amino acid parameter representations by artificial neural networks J. Mol. Model. 7 (9) 360-369